RWE Non-Interventional Prospective Study of Ribociclib Effectiveness and Safety in Patients With HR+/HER2- Early Breast Cancer in Saudi Arabia

RecruitingOBSERVATIONAL

Enrollment

177

Participants

Timeline

Start Date

August 27, 2025

Primary Completion Date

November 30, 2028

Study Completion Date

November 30, 2028

Conditions

HR+/HER2- Early Breast Cancer

Interventions

DRUG

ribociclib

This is an observational study. There is no treatment allocation. The decision to initiate ribociclib will be based solely on clinical judgement.

Trial Locations (1)

RECRUITING

Novartis Investigative Site, Riyadh